WO2004032855A2 - Methode d'inhibition de l'angiogenese faisant appel a des inhibiteurs du facteur de croissance transformateur beta 3 - Google Patents
Methode d'inhibition de l'angiogenese faisant appel a des inhibiteurs du facteur de croissance transformateur beta 3 Download PDFInfo
- Publication number
- WO2004032855A2 WO2004032855A2 PCT/US2003/031778 US0331778W WO2004032855A2 WO 2004032855 A2 WO2004032855 A2 WO 2004032855A2 US 0331778 W US0331778 W US 0331778W WO 2004032855 A2 WO2004032855 A2 WO 2004032855A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- beta
- growth factor
- transforming growth
- angiogenesis
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
Definitions
- transforming growth factor-beta 3 upregulation of transforming growth factor-beta 3 expression has been demonstrated in hepatocellular carcinoma cells and perineoplastic stroma of the liver, suggesting a role in tumor progression (Abou-Shady et al . , Am. J. Surg . , 1999, 177, 209- 215) . Furthermore, increased expression of transforming growth factor-beta 3 in breast cancer patients is a prognostic indicator inversely correlated with survival (Ghellal et al . , Anticancer Res . , 2000, 20 , 4413-4418).
- Aqueous suspensions may further contain substances that increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran.
- the suspension may also contain stabilizers.
- Pharmaceutical compositions include, but are not limited to, solutions, emulsions, foams and liposome-containing formulations.
- the pharmaceutical compositions and formulations used may comprise one or more penetration enhancers, carriers, excipients or other active or inactive ingredients.
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003275474A AU2003275474A1 (en) | 2002-10-07 | 2003-10-07 | Method for inhibiting angiogenesis with transforming growth factor-beta 3 inhibitors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41707402P | 2002-10-07 | 2002-10-07 | |
US60/417,074 | 2002-10-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004032855A2 true WO2004032855A2 (fr) | 2004-04-22 |
WO2004032855A3 WO2004032855A3 (fr) | 2005-06-02 |
Family
ID=32093960
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/031778 WO2004032855A2 (fr) | 2002-10-07 | 2003-10-07 | Methode d'inhibition de l'angiogenese faisant appel a des inhibiteurs du facteur de croissance transformateur beta 3 |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2003275474A1 (fr) |
WO (1) | WO2004032855A2 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008109548A2 (fr) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Composés d'acides nucléiques conçus pour inhiber l'expression du gène tgfb et utilisations de ceux-ci |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6673341B2 (en) * | 1998-07-06 | 2004-01-06 | Beth Israel Deaconness Medical Center | Methods of inhibiting proliferative diseases by inhibiting TGF-β-mediated angiogenesis |
-
2003
- 2003-10-07 WO PCT/US2003/031778 patent/WO2004032855A2/fr not_active Application Discontinuation
- 2003-10-07 AU AU2003275474A patent/AU2003275474A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6673341B2 (en) * | 1998-07-06 | 2004-01-06 | Beth Israel Deaconness Medical Center | Methods of inhibiting proliferative diseases by inhibiting TGF-β-mediated angiogenesis |
Non-Patent Citations (3)
Title |
---|
CAO Y. ET AL: 'Antiangiogenic Cancer Therapy' SEMINARS IN CANCER BIOLOGY vol. 14, April 2004, pages 139 - 145 * |
HOLIFIELD ET AL: 'TGF-B1, -B2 and -B3 Cooperate to Facilitate Tubulogenesis in the Explanted Quail Heart' JOURNAL OF VASCULAR RESEARCH vol. 41, March 2004, pages 491 - 498 * |
KIM ET AL: 'Transforming Growth Factor-B: Biology and Clinical Relevance' JOURNAL OF BIOCHEMISTRY vol. 38, no. 1, January 2005, pages 1 - 8 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008109548A2 (fr) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Composés d'acides nucléiques conçus pour inhiber l'expression du gène tgfb et utilisations de ceux-ci |
WO2008109548A3 (fr) * | 2007-03-02 | 2009-02-26 | Mdrna Inc | Composés d'acides nucléiques conçus pour inhiber l'expression du gène tgfb et utilisations de ceux-ci |
Also Published As
Publication number | Publication date |
---|---|
WO2004032855A3 (fr) | 2005-06-02 |
AU2003275474A8 (en) | 2004-05-04 |
AU2003275474A1 (en) | 2004-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4762889B2 (ja) | 血管形成及び腫瘍成長を阻止するための核酸化合物 | |
AU2002344237B8 (en) | Nucleic Acid Based Modulation of Female Reproductive Diseases and Conditions | |
KR101749352B1 (ko) | Sirt1에 대한 천연 안티센스 전사체의 억제에 의해 sirt1 관련된 질환의 치료 | |
US8410067B2 (en) | Inhibition of versican with siRNA and other molecules | |
EP2596807A1 (fr) | Aptamères de liaison complémentaires et agents anti-C5 utiles dans le traitement des troubles oculaires | |
EP1716235B1 (fr) | Inhibiteurs de la signalisation cellulaire liée au tgf-beta/tgf-r pour le traitement des maladies neurodégénératives | |
US20060122136A1 (en) | Effective and stable DNA enzymes | |
US20090270487A1 (en) | Compositions and methods for inhibiting the synthesis or expression of MMP-1 | |
KR20090042297A (ko) | IOP―관련 증상을 치료하기 위한 그렘린의 RNAi 매개 억제 | |
US8129354B2 (en) | Treatment of neurological disorders by dsRNA administration | |
AU673537B2 (en) | Antisense polynucleotides | |
CA2860676A1 (fr) | Compositions organiques pour traiter des maladies associees a la beta-catenine | |
US20090028862A1 (en) | Emmprin antagonists and uses thereof | |
US20060258610A1 (en) | Modulation of STAT 6 expression for the treatment of airway hyperresponsiveness | |
WO2018136831A1 (fr) | Compositions de pseudo-nœuds et méthodes pour inhiber le facteur d | |
WO2004032880A2 (fr) | Methode permettant d'inhiber l'angiogenese a l'aide d'inhibiteurs ship-1 | |
EP3452593B1 (fr) | Lncrna meg3 pour la thérapie et le diagnostic du remodelage cardiaque | |
WO2004032855A2 (fr) | Methode d'inhibition de l'angiogenese faisant appel a des inhibiteurs du facteur de croissance transformateur beta 3 | |
EP1325955A1 (fr) | Composés et méthodes pour l'identification et/ou la validation d'une cible | |
JP2009510174A (ja) | ブデソニドおよびil−4受容体アルファを標的化するアンチセンスオリゴヌクレオチドを用いた併用療法 | |
KR20200123165A (ko) | 돌연변이체 p53-특이적 siRNA를 이용하는 암 치료적 표적화 | |
EP2978847B1 (fr) | Ribozymes en tête de marteau ciblant mir-21 | |
WO2016011840A1 (fr) | Cible de la protéine vgsc bêta 3 de prévention, traitement, et détection diagnostique de cancers | |
WO2008109468A1 (fr) | Composés d'acide nucléique pour inhiber l'expression du gène mmp et utilisations de ceux-ci | |
KR20140021594A (ko) | 혈관 장벽 기능이 변경된 장애의 치료 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase in: |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |